Navigation Links
Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
Date:11/26/2008

MIAMI, Nov. 26 /PRNewswire/ -- Thomas K. Equels, President and Managing Director of the Equels Law Firm, has been elected to the board of directors for Hemispherx BioPharma, Inc. (Amex: HEB), a Philadelphia-based biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for the treatment of viral and immune-based disorders.

Equels' legal practice is devoted to litigation, with particular emphasis on civil racketeering, business torts and commercial matters. Prior to his board election, Equels served as Hemispherx BioPharma's litigation counsel.

For more than 25 years, Equels has represented national and state governments, and companies in the banking, insurance, aviation, pharmaceutical, construction and development industries. He has extensive experience in complex litigation matters including:

    -- Obtained a $26.8 million judgment in 2008 in a breach of contract
       action against Bear Stearns, for the Delaware Insurance Commissioner,
       related to an insolvent insurance company.
    -- Obtained a $15 million judgment in 2005 against boy band guru Lou
       Pearlman of Trans Continental Records, Inc.
    -- Obtained a $44 million judgment against Manuel Noriega for public money
       he misappropriated from the Republic of Panama.
    -- Recovered more than $100 million misappropriated and money laundered
       overseas by former insiders of a now defunct insurance company being
       liquidated by the State of Delaware's Insurance Commissioner.
    -- Obtained and collected a $10.6 million judgment against the FDIC for
       breach of contract involving a client's purchase of a national mortgage
       company owned by a failed savings and loan.
    -- Prosecuted a bank fraud claim against an international lender, which
       resulted in a jury awarding $2.6 million damages for fraud and an order
       invalidating a $9 million mortgage.

Equels earned a law degree with high honors from the Florida State University School of Law and earned a bachelor of arts degree, summa cum laude, from Troy State University. He is a member of The Florida Bar Association, the American Bar Association and the Academy of Florida Trial Lawyers.

About the Equels Law Firm

The Equels Law Firm has established itself as one of Florida's most effective and experienced law firms in the areas of complex litigation, government, business torts and personal injury law. The Equels Law Firm attorneys in Miami, Orlando and Tallahassee are known for providing high-quality, timely, efficient and personalized service to its local, national and international clients, whether representing them in either federal and state court or before federal, state or local governments. You can learn more about the Equels Law Firm at www.equelslaw.com or by calling Thomas Equels at (305) 859-7700.

About Hemispherx BioPharma

Hemispherx BioPharma, Inc. is a specialty pharma company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(R) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics, Ampligen(R) and Oragens. Ampligen(R) and Oragens represent experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 50 issued patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(R)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.


'/>"/>
SOURCE Equels Law Firm
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
3. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
4. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
5. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
6. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
7. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
8. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
9. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
10. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
11. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... -- Stock-Callers.com explores the Biotech industry to ... recent performances of select equities. In this morning,s lineup ... Abeona Therapeutics Inc. (NASDAQ: ABEO ), Theravance ... Therapeutics Inc. (NASDAQ: SAGE ). According to ... market size is expected to reach $604.40 billion by 2020 due to ...
(Date:1/20/2017)... 2017 http://www.Financialbuzz.com - ... leading causes of death worldwide. There were 8.2 million ... cancer related deaths increased gradually over time, the death ... of various cancers continues to drive demand of biological ... Global Market Insights, Inc. cancer biological therapy market size was ...
(Date:1/19/2017)... Jan 19, 2017 Research and Markets has ... Technology, Biomolecules, Cancer Type, Application - Global Opportunity Analysis and Industry ... ... the global market is projected to reach $15,737 million by 2022 ... 2016 to 2022. Omic technologies segment accounted for ...
(Date:1/19/2017)... Ky. and HOUSTON ... Inc. ("NX Prenatal") today announced the formation of ... together leading clinicians and industry veterans who enhance ... company as it accelerates development of its novel ... to provide medical, clinical and strategic guidance for ...
Breaking Biology Technology:
(Date:1/13/2017)... WASHINGTON, N.Y. , Jan. 13, 2017 /PRNewswire/ ... of technology solutions for the homecare industry, including ... of homecare industry expert, Justin Jugs, as Senior ... brings more than 15 years of homecare experience ... team in developing strategic plans to align Sandata,s ...
(Date:1/12/2017)... 12, 2017  New research undertaken by Fit Small ... future.  1,000 participants were simply asked which office technology had ... may consider standard issue.  Insights on what will ... gathered from futurists and industry leaders including Penelope Trunk ... .  Some of these findings ...
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a ... with the release of its patent-pending calibration device. With ... reliably perform calibrations, securely upload data logs and process ... the customer. "Fighting drunk driving through the ... the public at large, but also for the customer ...
Breaking Biology News(10 mins):